Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.

What Was Tested

This randomized controlled trial looks at Human Growth Hormone.

Who Took Part

The study group was 71 adults.

By PubMed's age tags, the people studied were children, teenagers, adults and middle-aged adults, both men and women.

BMD with dual energy X-ray absorptiometry, serum type I procollagen carboxy-terminal propeptide (PICP), serum type I collagen carboxy-terminal telopeptide (ICTP) and serum IGF-I were assessed in 71 adults with GH deficiency.

There were 44 men and 27 women, aged 20 to 59 (median 43) years.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Human Growth Hormone and who got the comparison, which limits bias.

As a double-blind Human Growth Hormone study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Age Factors, Biomarkers, Bone Density, Bone Remodeling, Collagen, Collagen Type I and Femur.

What This Means in Plain Language

The paper is a randomized and double-blind study of Human Growth Hormone in 71 adults.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (European journal of endocrinology), a journal based in England.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.